Stay updated on Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial page.

Latest updates to the Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial page
- Check5 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.3%
- Check12 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.0%
- Check19 days agoChange DetectedThe web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an updated version number from v2.16.0 to v2.16.1.SummaryDifference1%
- Check26 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.7%
- Check33 days agoChange DetectedThe page has removed the estimated timestamps for when results were first posted and last updated, which may affect users' understanding of the timeliness of the information provided.SummaryDifference0.5%
- Check40 days agoChange DetectedThe web page has undergone significant updates, including the termination of a study and the posting of results, with specific dates and metrics related to patient outcomes and adverse events now included. Key details about the study's phases, response rates, and safety evaluations have been clarified and expanded.SummaryDifference83%
Stay in the know with updates to Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial page.